Optinose Cancels Earnings Conference Call Following Acquisition Agreement with Paratek Pharmaceuticals

Optinose cancels earnings call due to acquisition agreement with Paratek Pharmaceuticals; results will be reported as planned.

Quiver AI Summary

Optinose has announced the cancellation of its earnings conference call for the quarter and full year ending December 31, 2024, which was scheduled for March 20, 2025. This decision comes in light of Optinose's agreement to be acquired by Paratek Pharmaceuticals, pending shareholder approval and other customary conditions. The company plans to report its financial results for the specified periods in due course. Optinose specializes in pharmaceuticals for patients treated by ear, nose, and throat and allergy specialists.

Potential Positives

Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, which could provide significant growth opportunities and resources for the company.
The acquisition is subject to shareholder approval and customary closing conditions, indicating the transaction is at an advanced stage and may lead to a successful completion.
The cancellation of the earnings conference call suggests a strategic focus on the acquisition process rather than on routine earnings announcements, highlighting a prioritization of corporate strategy.

Potential Negatives

The cancellation of the earnings conference call may indicate a lack of transparency regarding the company's financial status ahead of the acquisition.
The acquisition by Paratek Pharmaceuticals could raise concerns among investors about the future direction and management of Optinose.

FAQ

Why was the Optinose earnings conference call cancelled?

The earnings conference call was cancelled due to Optinose entering a definitive acquisition agreement with Paratek Pharmaceuticals.

When was the original earnings conference call scheduled?

The conference call was originally scheduled for March 20, 2025, at 8:00 a.m. Eastern Time.

What acquisition agreement did Optinose announce?

Optinose announced a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to customary closing conditions.

How does this affect Optinose's financial reporting?

Optinose expects to report its financial results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.

Where can I find more information about Optinose?

More information about Optinose can be found on their website at www.optinose.com or their social media pages on X and LinkedIn.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$OPTN Insider Trading Activity

$OPTN insiders have traded $OPTN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $OPTN stock by insiders over the last 6 months:

RAMY A MAHMOUD (Chief Executive Officer) has made 0 purchases and 3 sales selling 11,358 shares for an estimated $37,823.
MICHAEL F III MARINO (Chief Legal Officer & Corp Sec) has made 0 purchases and 3 sales selling 5,441 shares for an estimated $14,069.
PAUL JR. SPENCE (Chief Commercial Officer) sold 1,223 shares for an estimated $6,469

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$OPTN Hedge Fund Activity

We have seen 4 institutional investors add shares of $OPTN stock to their portfolio, and 59 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 1,102,790 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $7,366,637
MVM PARTNERS, LLC removed 973,684 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,504,209
ROSALIND ADVISORS, INC. removed 552,500 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,690,700
GREAT POINT PARTNERS LLC removed 487,140 shares (-56.8%) from their portfolio in Q4 2024, for an estimated $3,254,095
KINGDON CAPITAL MANAGEMENT, L.L.C. removed 373,282 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,493,523
BLEICHROEDER LP removed 269,675 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,801,429
VANGUARD GROUP INC removed 256,956 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,716,466

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$OPTN Analyst Ratings

Wall Street analysts have issued reports on $OPTN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

H.C. Wainwright issued a "Buy" rating on 01/03/2025
Piper Sandler issued a "Overweight" rating on 11/13/2024

To track analyst ratings and price targets for $OPTN, check out Quiver Quantitative's $OPTN forecast page.

Full Release

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.

The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions.

The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn .

Optinose Investor Contact
Jonathan Neely
[email protected]
267.521.0531